Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP550181.RAgm6qa-XXBETvigveALV6fkYrq1vudhocoyKRS97My3Q130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP550181.RAgm6qa-XXBETvigveALV6fkYrq1vudhocoyKRS97My3Q130_assertion type Assertion NP550181.RAgm6qa-XXBETvigveALV6fkYrq1vudhocoyKRS97My3Q130_head.
- NP550181.RAgm6qa-XXBETvigveALV6fkYrq1vudhocoyKRS97My3Q130_assertion wasGeneratedBy ECO_0000203 NP550181.RAgm6qa-XXBETvigveALV6fkYrq1vudhocoyKRS97My3Q130_provenance.
- NP550181.RAgm6qa-XXBETvigveALV6fkYrq1vudhocoyKRS97My3Q130_assertion wasDerivedFrom befree-20140225 NP550181.RAgm6qa-XXBETvigveALV6fkYrq1vudhocoyKRS97My3Q130_provenance.
- NP550181.RAgm6qa-XXBETvigveALV6fkYrq1vudhocoyKRS97My3Q130_assertion SIO_000772 19358724 NP550181.RAgm6qa-XXBETvigveALV6fkYrq1vudhocoyKRS97My3Q130_provenance.
- NP550181.RAgm6qa-XXBETvigveALV6fkYrq1vudhocoyKRS97My3Q130_assertion evidence source_evidence_literature NP550181.RAgm6qa-XXBETvigveALV6fkYrq1vudhocoyKRS97My3Q130_provenance.
- NP550181.RAgm6qa-XXBETvigveALV6fkYrq1vudhocoyKRS97My3Q130_assertion description "[As KRAS mutations are associated with poor response and resistance to EGFR-targeting drugs, this study was conducted to obtain more information on the spectrum of KRAS mutations in ovarian carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP550181.RAgm6qa-XXBETvigveALV6fkYrq1vudhocoyKRS97My3Q130_provenance.